Neuroimaging Study
Part of paid clinical trials in Jacksonville, Florida.
- Sponsor
- Mayo Clinic
- Study ID
- NCT03618186
- Phase
- PHASE2
- Status
- Enrolling By Invitation
Conditions
- Cognitive Impairment
Eligibility Criteria
- Sex
- ALL
- Age
- 30 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Tau PET scan — COMBINATION_PRODUCTPatient will receive a dose of flutaucipir and be scanned appropriately
Study Details
The researchers are trying to gather information and learn more about imaging tests in racially different people who are cognitively normal or have dementia.
Key Dates
- First listed
- Aug 7, 2018
- Start date
- Nov 26, 2018
- Status verified
- Jun 2026
- Primary completion
- May 31, 2030
- Completion
- May 31, 2030
Study Design
- Enrollment
- 240 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- DIAGNOSTIC
Arms
- Experimental: Normal controlCognitively normal volunteers
- Experimental: Mild Cogntive impairmentPerson with cognitive impairment that meet Peterson Criteria
- Experimental: DementedPatient's that meet dementia criteria
Primary Outcome Measure
Tau positive scans [ Time Frame: 5 years ]
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic in Florida | Jacksonville | Florida | 32224 | - |
| Mayo Clinic Minnesota | Rochester | Minnesota | 55905 | - |
Find similar trials in Jacksonville, FL
Related Studies
- Neurologic Stem Cell Treatment StudyRecruiting · MD Stem Cells · Westport, Connecticut
- A Mechanistic Study to Investigate tDCS and Working Memory in MCI PatientsRecruiting · University of Florida · Gainesville, Florida
- Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)Enrolling By Invitation · Cognito Therapeutics, Inc. · Phoenix, Arizona
- Study of ALTO-101 in Patients With SchizophreniaPHASE2 · Recruiting · Alto Neuroscience · Garden Grove, California